Cargando…

The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2

BACKGROUND: Avidity is defined as the strength of binding between immunoglobulin G (IgG) and its specific target epitope. IgG of high avidity is established during affinity maturation. Failure to achieve high avidity IgG may result in a lack of protective immunity towards infection and disease. It i...

Descripción completa

Detalles Bibliográficos
Autor principal: Bauer, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944804/
https://www.ncbi.nlm.nih.gov/pubmed/33713819
http://dx.doi.org/10.1016/j.ijid.2021.01.061
_version_ 1783662746361921536
author Bauer, Georg
author_facet Bauer, Georg
author_sort Bauer, Georg
collection PubMed
description BACKGROUND: Avidity is defined as the strength of binding between immunoglobulin G (IgG) and its specific target epitope. IgG of high avidity is established during affinity maturation. Failure to achieve high avidity IgG may result in a lack of protective immunity towards infection and disease. It is known that the interaction between SARS-CoV-2 spike protein and its cellular receptor is driven by high affinity. Therefore, it is predictable that protective antibodies towards SARS-CoV-2 should show high affinity/avidity. AVIDITY AFTER SARS-COV-2 INFECTION: Recent findings by several groups demonstrate that the serological response towards infection with SARS-CoV-2 and seasonal coronaviruses is characterized by incomplete avidity maturation, followed by a decline of the serological response. This response might facilitate reinfection, prevent herd immunity and potentially allow repeated cycles of infection. CONSEQUENCES FOR VACCINATION TOWARDS SARS-COV-2: Therefore, the sole focus on antibody titers reached after vaccination towards SARS-CoV-2 might not be sufficient to evaluate the degree of achieved protection. Rather, it is suggested to include avidity determination to optimize vaccination protocols and achieve high avidity IgG directed towards SARS-CoV-2 through vaccination. Avidity determination might also be useful to control for truly protective immunity towards SARS-CoV-2 in individual cases.
format Online
Article
Text
id pubmed-7944804
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-79448042021-03-11 The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2 Bauer, Georg Int J Infect Dis Article BACKGROUND: Avidity is defined as the strength of binding between immunoglobulin G (IgG) and its specific target epitope. IgG of high avidity is established during affinity maturation. Failure to achieve high avidity IgG may result in a lack of protective immunity towards infection and disease. It is known that the interaction between SARS-CoV-2 spike protein and its cellular receptor is driven by high affinity. Therefore, it is predictable that protective antibodies towards SARS-CoV-2 should show high affinity/avidity. AVIDITY AFTER SARS-COV-2 INFECTION: Recent findings by several groups demonstrate that the serological response towards infection with SARS-CoV-2 and seasonal coronaviruses is characterized by incomplete avidity maturation, followed by a decline of the serological response. This response might facilitate reinfection, prevent herd immunity and potentially allow repeated cycles of infection. CONSEQUENCES FOR VACCINATION TOWARDS SARS-COV-2: Therefore, the sole focus on antibody titers reached after vaccination towards SARS-CoV-2 might not be sufficient to evaluate the degree of achieved protection. Rather, it is suggested to include avidity determination to optimize vaccination protocols and achieve high avidity IgG directed towards SARS-CoV-2 through vaccination. Avidity determination might also be useful to control for truly protective immunity towards SARS-CoV-2 in individual cases. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-05 2021-03-10 /pmc/articles/PMC7944804/ /pubmed/33713819 http://dx.doi.org/10.1016/j.ijid.2021.01.061 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Bauer, Georg
The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2
title The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2
title_full The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2
title_fullStr The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2
title_full_unstemmed The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2
title_short The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2
title_sort potential significance of high avidity immunoglobulin g (igg) for protective immunity towards sars-cov-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944804/
https://www.ncbi.nlm.nih.gov/pubmed/33713819
http://dx.doi.org/10.1016/j.ijid.2021.01.061
work_keys_str_mv AT bauergeorg thepotentialsignificanceofhighavidityimmunoglobulingiggforprotectiveimmunitytowardssarscov2
AT bauergeorg potentialsignificanceofhighavidityimmunoglobulingiggforprotectiveimmunitytowardssarscov2